S. 3385 · 118th Congress
A bill to prohibit contracting with certain biotechnology providers.
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 118th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
R
HagertySponsorNo cosponsors.
This bill prohibits federal contracting with certain biotechnology providers connected to foreign adversaries, with exceptions.
What it does: CRS summary · Introduced in Senate · Dec 4, 2023
This bill prohibits federal contracting with certain biotechnology providers connected to foreign adversaries, with exceptions.
Specifically, the bill prohibits executive agencies from (1) procuring, obtaining, extending, or renewing a contract to procure or obtain any biotechnology equipment or service produced or provided by a biotechnology company of concern; or (2) entering into a contract or extending or renewing a contract that uses such equipment or service or that will require the direct use of such equipment or services. Those agencies may not obligate or expend loan or grant funds for such purposes.
A biotechnology company of concern includes BGI Group, MGI Group, Complete Genomics, any subsidiary, parent affiliate, or successor of such entities, and any entity that
- is subject to the jurisdiction, direction, or control of a foreign adversary;
- operates primarily in the biotechnology industry; and
- the Department of Defense (DOD) deems to pose a risk to national security.
DOD must determine, within 90 days after this bill's enactment, whether WuXi AppTec, Axbio, and any subsidiary, affiliate, or successor of such entities, or any other entity headquartered in or organized under the laws of China, is a biotechnology company of concern.
Executive agencies may waive the prohibitions on a case-by-case basis under specified circumstances.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: A bill to prohibit contracting with certain biotechnology providers.
Latest action (Dec 4, 2023): Read twice and referred to the Committee on Homeland Security and Governmental Affairs.
Policy area: Government Operations and Politics · Origin: Senate · Introduced: Dec 4, 2023
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.